Herald news services
BOTHELL — Seattle Genetics Inc. on Thursday announced it will start a second-phase clinical trial with one of its lead drug candidates, SGN-15.
The trial will evaluate the monoclonal antibody-drug conjugate SGN-15 in combination with the chemotherapeutic drug Taxotere for patients with hormone refractory prostate cancer. The study is planned for as many as 15 sites in the United States, with the lead site at Arizona Cancer Center in Tucson.
Talk to us
- You can tell us about news and ask us about our journalism by emailing newstips@heraldnet.com or by calling 425-339-3428.
- If you have an opinion you wish to share for publication, send a letter to the editor to letters@heraldnet.com or by regular mail to The Daily Herald, Letters, P.O. Box 930, Everett, WA 98206.
- More contact information is here.